Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-14
2008-12-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040
Reexamination Certificate
active
07470691
ABSTRACT:
The present invention relates to the use of compounds of formula (I)for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B1are as described in the specification.
REFERENCES:
patent: 5182280 (1993-01-01), Cuberes-Altisent et al.
patent: 5576319 (1996-11-01), Baker et al.
patent: 5700802 (1997-12-01), Curtis et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 5976497 (1999-11-01), Pollak et al.
patent: 6656935 (2003-12-01), Yamada et al.
patent: 2004/0002488 (2004-01-01), Cowart
patent: 01/19802 (2001-03-01), None
patent: 03/101994 (2003-12-01), None
Curtis et al. Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 585-588 (1999).
“Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets” by LeadDiscovery, Available at:www.leaddiscovery.co.uk/dossiers/MDI002/Sexual%20dysfunction.htm (2002).
Bendele et al., “Anti-inflammatory activity of pergolide, a dopamine receptor agonist,” Journal of Pharmacology and Experimental Therapeutics 259:169-175 (1991).
Chen et al., “Effects of dopamine, apomorphine, γ-hydroxybutyric acid, haloperidol and pimozide on reflex bradycardia in rats1,” Journal of Pharmacology and Experimental Therapeutics 214:427-432 (1980).
Coward et al., “Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors,” Analytical Biochemistry 270:242-248 (1999).
Hahn et al , “Primate cardiovascular responses mediated by dopamine receptors: effects of N,N-di-n-propyldopamine and LY171555,” Journal of Pharmacology and Experimental Therapeutics 229:132-138 (1984).
Hrib, “the dopamine D4receptor: a controversial therapeutic target,” Drugs of the Future 25(6):587-611 (2000).
IUPAC Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. 45:13-30 (1976).
Lissoni et al., “Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia,” Neuroendocrinology Letters 21:405-408 (2000).
Melis et al., “Dopamine and sexual behavior,” Neuroscience and Biobehavioral Reviews 19(1):19-38 (1995).
Missale et al., “Dopamine receptors: from structure to function,” Physiological Reviews 78:189-225 (1998).
Prescott, Methods in Cell Biology, vol. XIV, Academic Press, New York, NY p. 33 et seq. (1976).
Cowart Marlon D.
Latshaw Steven P.
Nelson Sherry L.
Stewart Andrew O.
Abbott Laboratories
Bernhardt Emily
Donner B. Gregory
LandOfFree
Fused bicyclic aromatic compounds that are useful in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused bicyclic aromatic compounds that are useful in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused bicyclic aromatic compounds that are useful in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042175